Nektar Therapeutics (Nasdaq: NKTR), a biopharmaceutical company, announced on Thursday its financial results for the full year ended 31 December 2019.
The company reported revenue for the year ended 31 December 2019 at USD114.6m as compared to USD1.2bn in 2018.
The firm posted total operating costs and expenses for 2019 at USD554.7m as compared to USD505.4m in 2018.
Net loss for the year ended 31 December 2019 was USD440.7m or USD2.52 diluted loss per share as compared to net income of USD681.3m or USD3.78 diluted earnings per share in 2018.
Howard W Robin, Nektar's president and CEO, commented, 'Nektar's progress over the past year has established a strong foundation for growth, with a robust portfolio of clinical-stage immuno-oncology and immunology candidates addressing multiple therapeutic areas.'
Lilly declares Q2 2025 dividend
Bruker acquires majority stake in RECIPE to expand clinical mass spectrometry diagnostics
Emmaus Life Sciences reports drop in revenues, increased loss in 2024
L'Oréal and WHO Foundation partner to expand global skin health access